Vedolizumab, TNF blockers for IBD pose no new or recurrent cancer risk
Among inflammatory bowel disease (IBD) patients with a current or prior malignancy, treatment with vedolizumab or antitumour necrosis factor (anti-TNF) does not bear an increased hazard of developing new or recurrent cancer, as shown in a study.
Vedolizumab, TNF blockers for IBD pose no new or recurrent cancer risk
19 Nov 2020